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Amouse model was developed for in vivomonitoring of infection and the effect of antimicrobial treatment against Staphylococ-
cus aureus biofilms, using the [18F]fluoro-deoxyglucose–MicroPET ([18F]FDG-MicroPET) image technique. In the model, sealed
Vialon catheters were briefly precolonized with S. aureus strains ATCC 15981 or V329, which differ in cytotoxic properties and
biofilmmatrix composition. After subcutaneous implantation of catheters in mice, the S. aureus strain differences found in bac-
terial counts and the inflammatory reaction triggered were detected by the regular bacteriological and histological procedures
and also by [18F]FDG-MicroPET image signal intensity determinations in the infection area and regional lymph node. Moreover,
[18F]FDG-MicroPET imaging allowed the monitoring of the rifampin treatment effect, identifying the periods of controlled in-
fection and those of reactivated infection due to the appearance of bacteria naturally resistant to rifampin. Overall, the mouse
model developed may be useful for noninvasive in vivo determinations in studies on S. aureus biofilm infections and assessment
of new therapeutic approaches.
Often, in vivo bacterial biofilms are inadvertently undetectedsince viable bacteria are shed only periodically. This hampers
diagnosis, which often requires puncture biopsy and/or surgery,
with the associated cost, morbidity, and mortality. Staphylococcus
aureus is one of themost frequent device-associated pathogens. In
staphylococcal biofilms, bacterial cells are interconnected by dif-
ferent types of polymericmatrices, including, among others, those
composed of polysaccharide intercellular adhesin (PIA), also
known as [polymericN-acetyl--(1,6)-glucosamine] (PNAG), or
proteins such as Bap (1–7). Of these, PIA/PNAGmatrices are par-
ticularly common in clinical isolates (2) and medical device-re-
lated biofilm infections by S. aureus (mainly methicillin-suscepti-
ble S. aureus [MSSA]) and Staphylococcus epidermidis (8, 9).
Subcutaneous catheters have been successfully used in models
that simulate natural device-related staphylococcal infections.
However, with the use of nonsealed catheters in these models, the
biofilmmay be developed inside the catheter lumen, allowing only
a partial interaction between bacteria and the immune system cells
(10, 11).
Although S. aureus biofilm infections have been widely char-
acterized and quantified, especially in vitro, an experimental non-
invasive model to assess biofilm infections by natural or geneti-
cally modified bacteria is still needed to monitor in vivo infection
and treatment efficacy in preclinical studies. One of the most use-
ful animal models developed so far requires the use of biolumi-
nescent S. aureus bacteria genetically modified to contain lux
genes (12, 13). The use of this method is particularly limited when
infections are caused by nonbioluminescent bacteria or in long-
term studies, in which loss of bioluminescence may occur (14).
Positron emission tomography (PET) with [18F]fluoro-deoxy-
glucose ([18F]FDG), an in vivo nuclear medicine imaging tech-
nique requiring the administration of this glucose analog radio-
tracer, is being successfully applied in clinical infections, since this
radiotracer is metabolized by many infectious and inflammatory
cells (15). This technique has been proposed for early detection of
different infectious processes (16) and also in combination with
magnetic resonance imaging for clinical and biomedical research
(17). The main advantages of PET over other imaging techniques
are its high sensitivity and the possibility to perform quantitative
measurements in the images generated. In animals, [18F]FDG-
MicroPET has been used in different rabbit osteomyelitis models
(18, 19). The most recent one was performed to detect staphylo-
coccal infections in bone and compare S. aureus and S. epidermidis
infections (18).
The aim of our study was to determine the utility of a nonin-
vasive [18F]FDG-MicroPET in vivo imaging technology, using a
sealed-catheter mouse model, in order to assess in vivo infection
differences between S. aureus biofilm-producing strains and to
monitor as well the effect of antimicrobial treatment in longitudi-
nal studies. Results regarding strain virulence, inflammatory re-
sponses, and the [18F]FDG-MicroPET signal were investigated.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Two S. aureuswild-type strains
(ATCC 15981 and V329) having a high capacity to form biofilms but
triggering different types of infections (clinical and subclinical, respec-
tively) were used. Strain ATCC 15981 was from a human clinical otitis
patient. This bap-negative strain contained genes encoding exocellular
proteases (20) and formed a highly adherent hyperbiofilm with an ica-
dependent PIA/PNAGpolysaccharidicmatrix (21). Strain V329 was from
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bovine subclinical mastitis (1), produced a Bap protein biofilm matrix
(21) expressed in a stable ica-independent manner in vivo (22), and had a
very low pathogenicity in experimental animal infections (23). These
strains were kindly provided by I. Lasa (Instituto de Agrobiotecnología,
Pamplona, Spain) and J. Penadés (University of Glasgow, Glasgow,
United Kingdom), respectively.
S. aureus bacteria were cultured (37°C, 18 h) in tryptone soy agar
(TSA; Laboratorios Conda, Spain) or tryptone soy broth (TSB; Laborato-
rios Conda, Spain) supplemented with glucose (0.25%, wt/vol) (TSA-glc
and TSB-glc, respectively). The bacterial concentration was first adjusted,
spectrophotometrically and by dilution in TSB-glc, to 1 105 bacteria/ml
for catheter infection. Exact doses (CFU/ml) were retrospectively assessed
by serial 10-fold dilutions in phosphate buffer saline (PBS; pH 7.4), by
plating (37°C, 18 h) 100l in triplicate (limit of detection, 3.3 CFU/ml) in
TSA-glc, and incubation (37°C, 18 h).
Mouse model of S. aureus sealed-catheter infection. Female CD1
mice (Charles River International) of 20- to 22-g body weight were ac-
commodated in the animal facilities of the Universidad Pública de Na-
varra (UPNA; registration code ES/31-2016-000002-CR-SU-US), with
water and food ad libitum. Mouse handling and procedures were per-
formed in compliance with the current European and national regula-
tions, following the FELASA andARRIVEwelfare guidelines, andwith the
supervision of the UPNA’s Comité de Ética, Experimentación Animal y
Bioseguridad (CEEAB) and approval by the competent authority (Gobi-
erno de Navarra).
To prepare implants, commercial Vialon 18G1.3- by 30-mmcatheters
(Becton-Dickinson) were cut into 20-mm segments and sealed under
sterile conditions with petrolatum and tissular glue (Vetbond; 3MEspaña
S.A.). Cleaning and disinfectionwere achieved thereafter by immersion in
DD445 (A&BLaboratorios de Biotecnología) and ethanol (15min in each
solvent). Sterility was checked by incubation (37°C, 24 h) in TSB. Then,
reliable S. aureus catheter precolonization was successfully achieved by
incubation (37°C, 4 h) in 1 ml TSB-glc containing 1  105 CFU, as pre-
viously reported (10). The number of bacteria adhered to implants prior
to infectionwas systematically assessed. Finally, catheterswere rinsedwith
fresh TSB-glc and immediately implanted subcutaneously through amin-
imal surgical incision in the interscapular area of mice, previously anes-
thetized by intraperitoneal administration of ketamine (100 mg/kg of
body weight; Imalgene; Merial Laboratorios, S.A.) and xylacine (10 mg
kg1; Rompun; Bayer Health Care). In each experiment, nonprecolo-
nized but TSB-glc-treated catheters were subcutaneously implanted in
control mice.
Experimental design. Following implantation, four main animal ex-
periments were carried out. A detailed description of each experiment is
included below, and animal group distribution and assessment time
points are summarized in Fig. 1.
Clinical and bacteriological studies. After catheter implantation in
groups of 50 CD1mice, animals were examined daily by palpation for the
presence of catheter and signs of local infection through a 6-week period,
and the number of bacteria adhered to the catheter was determined just
before implantation (as baseline control) as well as at days 1, 2, 3, 4, and 7
and then weekly for 6 weeks postimplantation (PI) (Fig. 1A). For this, 5
mice per bacterial strain were euthanized by cervical dislocation and cath-
eters were aseptically removed, homogenized in 1 ml PBS by ultrasound
bath (40 to 50 Hz, 30 min; Selecta), and vortexed (1 min). The number of
CFU per catheter was determined by serial 10-fold dilution of homoge-
nates in PBS, plating 100 l by triplicate in TSA, and incubation of plates
(37°C, 18 to 24 h). Finally, the mean and standard deviation (SD) (n 5)
in log10 CFU/catheter were calculated.
Histopathological analysis and lesion score.Histological studies us-
ing hematoxylin and eosin (H&E) and immunohistochemical (IHC)
staining were carried out in the subcutaneous tissue area surrounding the
catheter implanted inmice, according to the scheme illustrated in Fig. 1B.
For this, sealed catheters precolonized with S. aureus strain ATCC 15981
or V329 as described above were implanted subcutaneously in groups of
15 CD1mice, and tissue samples containing the catheter and surrounding
tissues (adipose, muscular, and connective) were obtained at 1, 7, and 14
days PI (n 5) and fixed for 24 h in 10%buffered formaldehyde solution.
An additional group of 3 mice carrying sealed catheters preincubated in
TSB-glc alone were used (n  1) as uninfected controls. Five transaxial
slices of tissues obtained every 2 to 3 mmwere embedded in paraffin, and
then, 4- to 6-m sections were stained with H&E by standard procedures
and examined for four histological features: (i) local inflammatory reac-
tion by infiltration of polymorphonuclear leukocytes or mononuclear
cells around the catheter; (ii) cellular debris and acellular exudates be-
tween the catheter and the inflammatory reaction; (iii) fibrosis and en-
capsulation of the reaction around the catheter; and (iv) diffuse inflam-
matory reaction located between the adipose, muscular, and other
peripheral tissues. Lesionswere scored on a scale of 0 to 4 (0, absent to very
low; 1, mild; 2, moderate; 3, strong; 4, very strong).
Similar sections were stained for IHC studies to specifically detect the
antigen PIA/PNAG (strain ATCC 15981) or Bap (strain V329). These
sections were subjected to antigen retrieval by heating the slides in a pres-
sure cooker for 3 min in distilled water, pH 4.0. The IHC staining was
performed using polyclonal rabbit antibodies to PIA/PNAG and Bap,
kindly provided by J. Pier (Harvard Medical School, USA) and J. Valle
FIG 1 Design of the four mouse assays (A to D) performed in this work,
according to animal group distribution and time points for analysis (indicated
with arrows). (A) Bacteriological study on the evolution of infections (log10
CFU/catheter); (B) histological changes in subcutaneous tissue during infec-
tion, using hematoxylin and eosin (H&E) and immunohistochemical (IHC)
staining; (C) in vivo [18F]FDG-MicroPET imaging in an infection follow-up
study; (D) [18F]FDG-MicroPET imaging and bacteriological study (log10
CFU/catheter) in mice carrying infected catheters and then treated (T) daily
for 1 week with rifampin (0.5 mg/day/mouse) or receiving PBS (untreated
controls). Experiments illustrated in panels A, B, and C were carried out each
independently with strains S. aureusATCC 15981 and V329 and also included
animal groups with uninfected catheters (control groups). The experiment
shown in panel D was done with strain ATCC 15981.
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(CSIC-Instituto de Agrobiotecnología, Spain), respectively. Primary an-
tibodies were diluted 1:750 (PIA/PNAG) and 1:500 (Bap) with Dako an-
tibody diluent (Dako Denmark A/S), and the reaction products were de-
tected by using a Dako horseradish peroxidase (HRP) rabbit secondary
antibody (Dako,DenmarkA/S). Tissue preparations frommice carrying a
noninfected sealed catheter were used as control. Additionally, conven-
tional rabbit serum (product reference R9133; Sigma) was used as pri-
mary antibody control for the IHC technique specificity. Images were
observed and digitalized using an Olympus Vanox AHBS3 microscope
coupled to an Olympus DP12 digital camera.
Cytotoxicity assay. Cytotoxicity was measured by assessing the cyto-
lytic effect of bacterial extracts, as described previously (24) but using the
MDTF (Mus dunni tail fibroblast) murine cell line as targets. Briefly, bac-
terial extracts obtained from S. aureus strains ATCC 15981 or V329 were
diluted (1:10, 1:100, and 1:1,000) in PBS and incubated (37°C, 5% CO2)
with 1 105MDTF cells (reaching confluence)/well in 24-well plates (BD
Biosciences) for 90 min. PBS-treated cell extracts were used as control.
After incubation, cells were rinsed with PBS, detached with trypsin, cen-
trifuged (1,000 g, 5 min), and fixed with formalin. The number of live
cells was determined by flow cytometry (FACS Scalibur, BD Biosciences).
[18F]FDG-MicroPET in vivo monitoring of biofilm infections.
Sealed catheters precolonized with either ATCC 15981 or V329 S. aureus
strains were implanted subcutaneously in a total of 15 mice, as described
above. An additional group of 15 mice carrying catheters pretreated with
TSB-glc alone (see above) was used as uninfected control (Fig. 1C). Re-
sults were assessed in 3 independent experiments (5 mice per strain and
experiment). Following catheter implantation, infection was longitudi-
nally evaluated in vivo (n 5) by [18F]FDG-MicroPET on days 1, 7, and
14. For this, fasted mice were anesthetized with 2% isoflurane in O2 gas
and intravenously injectedwith 18.8 1.9MBq of [18F]FDG. Following 1
h of radiotracer uptake under continuous anesthesia inhalation, PET im-
aging was performed in a small-animal tomograph (MicroPET; Mosaic;
Philips, USA) by laying mice in prone position and capturing images for
15 min. Images were reconstructed using the three-dimensional (3D)
Ramla algorithm (a true 3D reconstruction) with 2 iterations and a relax-
ation parameter of 0.024 into a 128 by 128matrix with a 1-mm voxel size,
applying dead time, decay, random, and scattering corrections.
For [18F]FDG uptake assessment, MicroPET images were analyzed
using the PMOD software (PMOD Technologies Ltd., Adliswil, Switzer-
land), and semiquantitative results were expressed as the standardized
uptake value (SUV) index, obtained by normalization with the formula
SUV  [(RTA/cm3)/RID]  BW, where RTA is the radiotracer tissue
activity (in becquerels), RID is the radiotracer injected dose (in Bq), and
BW is the mouse body weight (in grams). After qualitative inspection of
the images, volumes of interest (VOI) were manually drawn on coronal
1-mm-thick consecutive slices including the entire catheter area and ax-
illary lymph nodes (ALN). For catheter image quantification, to avoid
manual bias of surrounding areas, a new VOI was generated semiauto-
matically using the threshold of 60% of maximum pixel for SUV mean
calculation (SUV60 index). Due to the small size of ALN, [18F]FDG up-
take was quantified and expressed as the mean of the 5 pixels with the
highest uptake (SUVmax) included in the VOI selected (25).
[18F]FDG-MicroPET in vivo monitoring of antimicrobial therapy
against S. aureus ATCC 15981 biofilm infection. Sealed catheters pre-
colonized with S. aureus ATCC 15981 were implanted subcutaneously in
20 mice, as described above. From day 1 to day 7, 10 of these mice were
treated daily with 0.1 ml of rifampin at 5 mg/ml diluted with PBS (0.5
mg/mouse of Rifaldin; Sanofi-Aventis, France) by the oroesophagical
route (Fig. 1D). The remaining 10 mice received PBS and were used as
untreated controls. At days 1, 7, and 14 PI, a subgroup of mice (n  5)
were arbitrarily selected from both the untreated and the treated groups
and monitored by [18F]FDG-MicroPET image analysis (see above). At 7
and 14 days PI, the 5 mice used for MicroPET image were also used for
determining the number of CFU/catheter, 24 h after radiotracer admin-
istration (when it was completely cleaned from the animal). Moreover,
resistance to rifampin was assessed in a pool of recovered colonies, ac-
cording to the standard MIC microdilution broth method (26).
Statistical analysis.TheKolmogorov-Smirnov test was first applied to
assess the normal distribution of data. Statistical comparison of means
was performed by one-way analysis of variance (ANOVA) (CFU data) or
repeated-measures ANOVA (MicroPET data) tests, followed by Fisher’s
protected least significant difference (PLSD) test. Mathematical and sta-
tistical analyses were performed using StatViewGraphics for Windows
(SAS Institute Inc.).
RESULTS
Differences between S. aureus strains in clinical evaluation, in
vivo kinetics of bacteria adhered to the surface of catheters, and
in vitro cytotoxicity. Signs of sepsis or discomfort were not found
in anymice throughout the experimental period. Upon palpation,
the majority of the animals with infected catheters had local sub-
cutaneous inflammatory reactions on the back by day 7 PI, which
were stronger for strain ATCC 15981 than for strain V329. The
number of viable bacteria adhered to the surface of sealed cathe-
ters was in all cases around 0.8 105 CFU at the time of implan-
tation, for both bacterial strains. Thereafter, S. aureus ATCC
15981 persisted on catheters at high levels (around 6 log CFU/
catheter) up to day 14 PI (Fig. 2), butmost (21 of 25) of the devices
were naturally expelled before this period. In contrast, all mice
with S. aureus V329 infection maintained the catheters through-
out the experimental period. In these mice, the number of viable
V329 bacteria adhered to catheters increased moderately from
days 1 to 3 PI, persisting thereafter at stable levels, around 4 to 5
log CFU/catheter (Fig. 2). Systematically, 1 of the 5 mice analyzed
per experimental group receiving S. aureus V329-precolonized
catheters was found free of infection from day 2 to the end of the
experiment, indicating a 20% decreased success of catheter infec-
tion persistence in vivo when using this strain. Comparatively,
mice carrying catheters successfully infected by V329 showed
lower (P 0.05) bacterial counts per catheter than those infected
by ATCC 15981 at any time point (up until day 14 PI, whenATCC
15981-infected catheters were no longer retained subcutane-
ously).
FIG2 Quantification (mean SD; n 5) of viable S. aureusATCC15981 and
V329 bacteria (CFU) found on infected sealed catheters precolonized with the
correspondent S. aureus strain and implanted subcutaneously in mice. Cath-
eters infected with strain ATCC 15981 (close squares) were naturally expelled
between days 7 and 14 postimplantation (PI). At each interval, 1 of 5 catheters
successfully precolonized in vitro with strain V329 became uninfected after
subcutaneous implantation in vivo, and the corresponding data have not been
included in the figure. Statistical comparisons by Fisher’s LSD test showed that
P values of0.05 (*) for comparisons between the two bacterial strains were
detected at days 1, 7, and 14.
Garrido et al.
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On the other hand, the in vitro cytotoxicity assay revealed that
the ATCC 15981 extract had a higher cytotoxic capacity than that
of strain V329. In fact, from the total MDTF viable cells counted
by fluorescence-activated cell sorter (FACS) (7,297.7 cellular
events counted in the untreated control), reductions of 44.2%
(3,225.2 dyed cells) and 5.1% (373.2 dyed cells) were detected
when ATCC 15981 and V329 extracts were used, respectively.
Overall, these results indicated the existence of in vivo bacterial
strain differences regarding the number of live bacteria on the
catheter and the capacity of triggering catheter expelling, which
could be related to the in vitro cytotoxicity of bacterial extracts.
Histopathology and immunohistochemistry. The above ob-
servations on infection dynamics and cytotoxicity encouraged the
study of inflammatory reactions, under the hypothesis that S. au-
reus ATCC 15981 and V329 infections would differ in the timing
(kinetics) and strength of immune/inflammatory reactions. His-
tological studies revealed that at day 1 PI, uninfected control mice
had only a mild diffuse edema and few neutrophils surrounding
the catheter area, both disappearing by day 7 PI (Fig. 3). This was
compatible with unspecific inflammation subsequent to the sur-
gical implantation of the catheter. In contrast, both bacterial bio-
film infections induced prolonged focal and diffuse inflammatory
responses, more intense in S. aureus ATCC 15981 than in V329
infections (Table 1). The focal reaction triggered by strain ATCC
15981 reached a maximum by day 7 and involved mainly neutro-
phils, fibroblasts, cell debris, and somemacrophages (Table 1 and
Fig. 3). The ATCC 15981-triggered reaction strength decreased by
day 14PI as a result of the natural expelling of cathetersmentioned
above (Table 1). Comparatively, strain V329 induced a delayed
focal inflammatory reaction characterized mainly by cell debris
(day 7) and macrophages (day 14), with no signs of remission.
Overall, these histological findings are in line with the cytotoxicity
differences observed in vitro, since focal reaction with cell debris
and neutrophil infiltration (Table 1 and Fig. 3) could be consid-
ered to be partially a result of bacterial cytotoxic effect and, in fact,
this effect was earlier and stronger in ATCC 15981 than in V329
infections.
Regarding the mouse connective capsule production, during
the first week of infection strain ATCC 15981 induced a thin cap-
sule that disappeared by day 14, accompanied by catheter expel-
ling. In contrast, the capsule induced by strain V329 appeared at
day 7 and became moderately thick by day 14 PI (Table 1).
As expected from the nature of the biofilm matrix and the
specificity of the anti-matrix-polymer antibodies used, the anti-
Bap and anti-PIA/PNAG antibodies stained specifically free bac-
teria, bacterial aggregates, and neutrophil-phagocytized bacterial
antigen in S. aureus strain V329 and ATCC 15981 infections, re-
spectively (Fig. 3H and I). Strikingly, anti-PIA/PNAG antibody
(and not anti-Bap or control normal rabbit serum) stained the
cytoplasm of foam cells disseminated far away from the catheter,
between the muscular and adipose tissues in the ATCC 15981 but
not in the V329 infection (Fig. 3I). Uninfected animals did not
yield positive reactionswith anti-PIA/PNAG, anti-Bap antibodies,
or control normal rabbit serum.
FIG3 Histological study on in vivo biofilm infections in subcutaneous tissues surrounding the catheter, stainedwithH&E (A toG) or by immunohistochemistry
techniques (H and I). Sealed catheters precolonized with S. aureus strains ATCC 15981 (A to C) or V329 (D to F) were implanted subcutaneously in mice, and
histological analysis was performed on days 1 (A andD), 7 (B and E), and 14 (C and F) PI. At day 14, all mice infected with ATCC 15981 had expelled the catheter
(C). Mice carrying uninfected catheters were used as controls (G). IHC allowed the detection of either Bap antigen in S. aureus V329 biofilm bacteria (H) or
PIA/PNAG antigen in foam cells of S. aureusATCC 15981 disseminated in tissues surrounding the catheter (I). 1, lumen; 2, catheter; 3, cell debris and infiltration
of neutrophils; 4, infiltration of macrophages; 5, fibroblasts and connective capsule (F).
S. aureus Bioﬁlm Monitoring by FDG-MicroPET in Mice
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In vivo ATCC 15981 and V329 infections monitoring by
MicroPET. Knowing the above strain differences, we examined
whether the two S. aureus infections could be assessed and would
differ in vivo by MicroPET imaging analysis, according to the ex-
periment outlined in Fig. 1C. Unlike what was observed in unin-
fected controls, [18F]FDGwas increased in both catheter andALN
areas of infected mice (Fig. 4).
In the catheter area (Fig. 4A and C, left panel), [18F]FDG up-
take was detected as soon as day 1 PI and remained stable for each
bacterial strain, without statistical differences in the mean SUV60
index values for a given strain along the study period. In addition,
strain differences were detected by increased (P  0.05) SUV60
values in ATCC 15981 compared to V329 infections on days 7 and
14 PI.
In ALN (Fig. 4B and C, right panel), SUVmax values were very
lowor null at day 1 PI, increasing significantly by day 7 PI inATCC
15981 infections but onlymoderately and with a delay (i.e., by day
14 PI) in V329 infections. Thus, differences between day 1 and
days 7 or 14 PI were highly significant (P  0.0005) in ATCC
15981 infection, but they were only a trend (P 0.08) in S. aureus
V329 infection. Overall, [18F]FDG uptake was detected in the
catheter area earlier than in ALN, but in ALN the signal remained
at high levels after catheter expelling, as presented in Fig. 4B.
Altogether, these results indicated that the early (day 7) and
strong [18F]FDG uptake observed in ATCC 15981 infection (Fig.
4) corresponded to an early and strong inflammatory reaction
(Fig. 3) and increased cytotoxicity triggered by this strain com-
pared to strain V329. Also, in V329-infected mice, the steady in-
crease in ALN SUVmax index corresponded to the steady increase
in focal subcutaneous inflammatory reaction (Fig. 3).
[18F]FDG-MicroPET image analysis for evaluating the effect
of a rifampin treatment. The strong and stable [18F]FDG uptake
in S. aureus ATCC 15981 infections suggested that this strain was
a good choice as a prototype to determine the utility of the
[18F]FDG-MicroPET mouse model for monitoring in vivo the ef-
fect of an antibiotic treatment with rifampin as a standard drug
against S. aureus (Fig. 1D). As shown in Fig. 5, the SUV60 and
SUVmax values obtained in the untreated groupwere very close to
those obtained in the previous experiment (Fig. 4), indicating the
repeatability of themethod. The SUV60 values in the catheter area
(Fig. 5A and B, left panels) decreased significantly (P  0.05) by
day 7 in the rifampin-treated group. This decrease was accompa-
nied by a significant (P 0.005) decrease at day 7 in the number of
CFU/catheter (Fig. 5C). Also, treated animals maintained the
catheter beyond day 14, this being a sign of controlled infection.
However, an increase (P 0.05) in the SUV60 indexwas observed
at an individual level in some rifampin-treated animals by day 14
PI compared to day 7 (Fig. 5A, left panel). This fluctuation of
SUV60 values was likely due to the appearance of rifampin-resis-
tant variants of S. aureusATCC15981, as verified by theMIC assay
(16 g/ml for recovered colonies versus 0.025 g/ml for the ref-
erence strain). Finally, the SUVmax values in ALN of rifampin-
treatedmice were null until day 7 (Fig. 5A and B, right panels) and
increased slightly at day 14 PI (Fig. 5A, right panel).
DISCUSSION
The utility of an innovative [18F]FDG-MicroPET in vivo imaging
technology in S. aureus biofilm infections was assessed in a sealed-
catheter mouse model developed in this work. This mouse model
was found useful for (i) monitoring long-term S. aureus in vivo
infections in the same animal, (ii) detecting S. aureus strain differ-
ences in infection dynamics and pathogenicity, and (iii) evaluat-
ing the effect of antimicrobial therapy using unlabeled bacteria.
To our knowledge, this is the first work using the [18F]FDG-
MicroPET imagemethod for diagnosing andmonitoring bacterial
biofilm evolution in mice. This method has been successfully ap-
plied for diagnosing clinical inflammatory processes, especially
those involving neutrophils and macrophages (27, 28). However,
bacteria may also take up [18F]FDG in vivo, since PIA/PNAG-
dependent S. aureus biofilm production in vitromay be enhanced
by glucose supplementation (TSB-glc here). Unfortunately, the
technique did not distinguish the signal emitted exclusively by
bacteria from that generated by inflammatory cells. [18F]FDG-
MicroPET has also been used in animals, specifically in rabbit
staphylococcal osteomyelitis models (18, 19). The mouse model,
which involved the use of sealed catheters and required a one-step
TABLE 1 Inflammatory reaction observed with hematoxylin and eosin staining after subcutaneous implantation of sealed catheters in micea
Inflammatory reaction
Strength of reaction after catheter colonization with S. aureus strain:
ATCC 15981 V329
None (uninfected
controls)
1 DPI 7 DPI 14 DPIb 1 DPI 7 DPI 14 DPI 1 DPI 7–14 DPI
Focal 	 	  	 	 	 	 	
Cell debris 		 			 	 		 			 		  
Neutrophils 			 				 	 		 	 		 	 
Macrophages 	 		 		  	 			  
Fibroblasts 	 			 		  		 		  
Size of capsule 	 	   	 		  
Diffuse
Edema 			 	  			   			 
Neutrophils 			 		 	 		 	 		 	 
Macrophages  	    	  
Fibroblasts  			   			 		  
a Symbols:, absent to very low;	, low;		, moderate;			, strong;				, very strong. Number of animals/group/assessment day: n 5 for each of the infected groups and
n 1 for uninfected controls per time point.
b All mice infected with strain ATCC 15981 had expelled the catheters by 14 DPI, and data obtained then refer to these mice that had already lost the implants.
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rather than a two-step (10, 11) surgical procedure in the absence
of a cement block, simplified the assessment of direct host-patho-
gen interactions. In line with our observations, in a rabbit model
detecting bone staphylococcal infections, a direct relationship was
found between PET image intensity, degree of leukocyte infiltra-
tion, and increased virulence (in S. aureus compared to S. epider-
midis) (18). However, detection of S. aureus strain differences and
antibiotic monitoring was not attempted.
Both S. aureus strains involved in our studywere strong biofilm
producers to guarantee a successful catheter precolonization and
subsequently attempt chronic infection in mice. The SUV image
differences detected in vivo between bacterial strains were in con-
sonance not only with those found in infection kinetics and cyto-
toxicity differences but also with strain-associated differences in
bacterial dissemination and the triggered histological changes.
The strain differences in the in vivo colonization capacity may be
attributed to the defective primary binding of V329 Bap-synthe-
sizing bacteria via host molecules (29, 30) and to the tight cell-to-
cell Bap-mediated bonds compared to PIA/PNAG-mediated
binding (ATCC 15981 biofilms). The decreased inflammatory re-
action triggered by V329 compared to ATCC 15981 can be ex-
plained by the decreased number of bacteria adhered to the cath-
eters in vivo, the diminished cytotoxicity in vitro, and the natural
replacement of toxin genes by the bap gene in strain V329 (1, 23).
In contrast, the intense inflammatory reaction triggered by ATCC
15981 was expected, as this clinical otitis isolate, which encodes
exocellular proteases (21), had a high colonization capacity and
was highly cytotoxic, all of whichmay have triggered the expulsion
of infected catheters.
The finding that the [18F]FDG-MicroPET uptake in untreated
mice was delayed in the draining ALN compared to the catheter
areawas compatiblewith the development of an adaptive immune
response in the ALN within a 2-week period following the im-
mune response at the initial infection site. This is in agreement
with a previous study evaluating S. aureus-contaminated muscle
injury in rabbits through histological andmicrobiological analysis
(31), in which the draining lymph node provided a delayed signal
compared to that of the originally infected body site. Altogether,
these observations outline the utility of draining lymph node
[18F]FDG-MicroPET imaging in chronic infections.
Biofilm-embedded bacteria are tenacious and 100 to 10,000
times more resistant to antimicrobial treatment than nonembed-
FIG4 Representative [18F]FDG-MicroPET images inmice carrying catheters infectedwith S. aureus strains ATCC15981 orV329. Slices at dorsal (A) and ventral
(B) positions show [18F]-FGD uptake in catheter (arrows) or axillary lymph node (ALN; arrowheads) areas, respectively. Brain (b), heart (h), bladder (bl), and
spinal cord (sp) show physiological uptake of [18F]-FGD. In panels A and B, each image corresponds to a representative animal analyzed at days 1, 7, and 14 PI.
Images of uninfected controls (receiving only TSB-glc) are included on the left. (C) Box plots illustrating the evolution of the SUV60 index in S. aureus ATCC
15981 or V329 infections in the catheter area (left panel) and SUVmax in ALN (right panel). Statistical comparisons by Fisher’s PLSD test: *, P 0.05; **, P
0.005.
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ded bacteria, even in vitro (32, 33). Different studies show that
treatment with high doses of rifampin is effective against S. aureus
biofilm bacteria in vitro (33–35) and in vivo (12), but it leads also
to the appearance of rifampin-resistant variants carrying muta-
tions in the rpoB gene and consequently to increased bacterial
counts and optical imaging signal, as observed in studies on nat-
ural human device infections (36) and mouse intravenous cathe-
ter infections using lux-labeled bacteria (10, 13). Thus, the appear-
ance of resistant variants, verified in vitro, was not only expected
but also advantageous in our model since it allowed the detection
of variation in [18F]FDG-MicroPET uptake intensity through the
duration of the treatment. Finally, the absence of catheter expel-
ling and of PET image signal in ALN upon antibiotic treatment
could be considered indicative of antibiotic efficacy and points out
the value of ALN to assess immune response and infection prog-
ress in the model applied.
The [18F]FDG-MicroPETmouse model allowed follow-up in-
dividual studies, reducing the number of euthanized experimental
animals, in line with the current international guidelines on ani-
mal welfare. A promising near-infrared fluorescence imaging
mouse model using an alternative precolonized device (polymer
disk) to detect inflammation (reactive oxygen species produced by
inflammatory cells) upon implantation has been developed re-
cently (14). The utility of thismodel to assess differences in patho-
genicity between bacterial strains and to monitor the effect of
antibiotic therapy has not been reported so far.
Overall, the model was highly reproducible, with a low intra-
group or interexperiment variability; of note, the in vivo follow-up
studies using individually identified animals allowed an individual
evaluation of the infection. Also, the model and technology ap-
plied involve decreased attendant costs and manual laboratory
work, by minimizing the number of animals used, and could be
suitable for preclinical studies, as it could yield useful data to di-
agnose S. aureus biofilm infections and to develop, improve, and
monitor single and combined antimicrobial treatments. Finally,
the model could be successfully employed to assess in vivo differ-
ences between natural isolates and/or genetically modified bacte-
ria in virulence/pathogenicity and to investigate host-pathogen
interactions of clinical relevance in device-associated and biofilm
infections.
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